# Biosplice Therapeutics

**Canonical:** https://apis.io/providers/biosplice-therapeutics/  
**Website:** https://www.biosplice.com/  
**APIs profiled:** 0

Biosplice Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company headquartered in San Diego, California, founded in 2008 by Osman Kibar and known until its 2020 rename as Samumed, LLC (samumed.com still redirects to biosplice.com). The company develops first-in-class small-molecule therapeutics that act on novel components of the Wnt signaling pathway and on the regulation of alternative pre-mRNA splicing. Its lead program is lorecivivint, an investigational intra-articular knee injection for osteoarthritis, positioned against a stated unmet need of "over 50 million US patients suffer from osteoarthritis, with no drugs available to arrest the disease"; the candidate has completed Phase 3 study and a New Drug Application has been submitted to the U.S. Food and Drug Administration. Programs outside lorecivivint — neurology, diabetes and oncology — are developed by the company's affiliate TenaRx, Inc. The company is led by Erich Horsley (Chief Executive Officer) with Osman Kibar as Founder and Executive Chairman, Yusuf Yazici as Chief Medical Officer, Phil Wilson as Chief Financial Officer and Scott W. Bulcao as Chief Legal Officer. Biosplice is a drug-discovery and clinical-development organization, not a software vendor: biosplice.com is a small ASP.NET corporate site covering mission, board, management, advisors, programs, publications, news and careers, and the company publishes no developer program of any kind — no API, no SDK, no developer portal, no GitHub organization and no machine-readable API contract.

## Kin Score — 11.9 / 100 (minimal)

Scored 2026-08-17 under rubric 0.11.0. Trend: flat (+0.0 from 11.9).

| Facet | Score |
|---|---|
| Discoverability | 53.7 |
| Contract Quality | 0.0 |
| Governance | 0.0 |
| Operational Transparency | 0.0 |
| Developer Ergonomics | 6.5 |
| Commercial Clarity | 21.1 |

Regulatory layer — **Health**: 17.5 (matched via tags).

## Agent readiness — 0.0 (human-only)

| Dimension | Value |
|---|---|
| Spec Presence | no |
| Agentic Access | no |
| MCP Server | no |
| Auth Clarity | no |
| Idempotency | no |
| Error Semantics | no |
| OpenAPI Examples | no |
| Rate Limit Signal | no |
| Event Surface Described | no |
| Agent Skills | no |
| Well Known Catalog | no |
| Consent Identity | no |
| Agent Card | no |
| Dry Run Mode | no |

## Security (1)

- **Biosplice Therapeutics Domain Security** — TLSv1.3 · HSTS · DMARC

## Tags

Company, Biotechnology, Pharmaceuticals, Life Sciences, Drug Development, Clinical Trials, Osteoarthritis, Small Molecule Therapeutics, Health Care, San Diego

---

Profiled by [API Evangelist](https://apievangelist.com) and published on [APIs.io](https://apis.io/providers/biosplice-therapeutics/). Scores are computed from the provider's own public artifacts under a published rubric.